Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors

Journal of Medicinal Chemistry

Volumn 49, Issue 6, 2006, Pages 1855-1866

  Grunwald, Christian ^a   Rundfeldt, Chris ^a   Lankau, Hans Joachim ^a   Arnold, Thomas ^a   Höfgen, Norbert ^a   Dost, Rita ^a   Egerland, Ute ^a   Hofmann, Hans Jörg ^b   Unverferth, Klaus ^a  

^a Elbion AG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 CHLOROPHENYL) 4 MORPHOLIN 1 YL 1,5 DIHYDROIMIDAZOL 2 ONE; 1 (4 CHLOROPHENYL) 4 PIPERIDIN 1 YL 1,5 DIHYDROIMIDAZOL 2 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; IMIDAZOLE DERIVATIVE; PENTETRAZOLE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; PHARMACOPHORE; RAT; ROTAROD TEST; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; BINDING SITES; BRAIN; GABA ANTAGONISTS; IMIDAZOLES; MALE; MICE; MODELS, MOLECULAR; MORPHOLINES; PENTYLENETETRAZOLE; PIPERIDINES; PYRROLES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, GABA-A; ROTAROD PERFORMANCE TEST; SEIZURES;

EID: 33645419316     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0509400     Document Type: Article

References (73)

1. Löscher, W. New visions in the pharmacology of anticonvulsion. Eur. J. Pharmacol. 1998, 342, 1-13.
2. Wittchen, H. U.; Hoyer, J. Generalized anxiety disorder: nature and course. J. Clin. Psychiatry 2001, 62 (Suppl. 11), 15-19.
3. Himmelfarb, S.; Murrell, S. A. The prevalence and correlates of anxiety symptoms in older adults. J. Psychol. 1984, 116, 159-167.
4. Burke, W. J.; Folks, D. G.; McNeilly, D. P. Effective use of anxiolytics in older adults. Clin. Geriatr. Med. 1998, 14, 47-65.
5. A receptors. Trends Pharmacol. Sci. 1997, 18, 425-429.
6. A receptors. Brain Res. Brain Res. Rev. 1999, 29, 196-217.
7. Bonnert, T. P.; Mckernan, R. M.; Farrar, S.; le Bourdelles, B.; Heavens, R. P.; Smith, D. W.; Hewson, L.; Rigby, M. R.; Sirinathsinghji, D. J.; Brown, N.; Wafford, K. A.; Whiting, P. J. Theta, a novel y-aminobutyric acid type A receptor subunit. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9891-9896.
8. Korpi, E. R.; Mattila, M. J.; Wisden, W.; Lüddens, H. GABA(A)-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands. Ann. Med. 1997, 29, 275-282.
9. A receptor channels. Annu. Rev. Neurosci 1994, 17, 569-602.
10. Albaugh, P. A.; Marshall, L.; Gregory, J.; White, G.; Hutchison, A.; Ross, P. C.; Gallagher, D. W.; Tallman, J. F.; Crago, M.; Cassella, J. V. Synthesis and biological evaluation of 7,8,9,10-tetrahydroimi-dazo[1,2-c] pyrido[3,4-e]pyrimdin-5(6H)-ones as functionally selective ligands of the benzodiazepine receptor site on the GABA(A) receptor. J. Med. Chem. 2002, 45, 5043-5051.
11. Basile, A. S.; Lippa, A. S.; Skolnick, P. Anxioselective anxiolytics: can less be more? Eur. J. Pharmacol. 2004, 500, 441-451.
12. Haefely, W.; Martin, J. R.; Schoch, P. Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol. Sci. 1990, 11, 452-456.
13. Costa, E.; Guidotti, A. Benzodiazepines on trial: a research strategy for their rehabilitation. Trends Pharmacol. Sci. 1996, 17, 192-200.
14. Richards, J. G.; Martin, J. R. Binding profiles and physical dependence liabilities of selected benzodiazepine receptor ligands. Brain Res. Bull. 1998, 45, 381-387.
15. Medina, J. H.; Viola, H.; Wolfman, C.; Marder, M.; Wasowski, C.; Calvo, D.; Paladini, A. C. Overview -Flavonoids: A new family of benzodiazepine receptor ligands. Neurochem. Res. 1997, 22, 419-425.
16. Yasumatsu, H.; Morimoto, Y.; Yamamoto, Y.; Takehara, S.; Fukuda, T.; Nakao, T.; Setoguchi, M. The pharmacological properties of Y-23684, a benzodiazepine receptor partial agonist. Br. J. Pharmacol. 1994, 111, 1170-1178.
17. Schoch, P.; Moreau, J. L.; Martin, J. R., Haefely, W. E. Aspects of benzodiazepine receptor structure and function with relevance to drug tolerance and dependence. Biochem. Soc. Symp. 1993, 59, 121-134.
18. Tang, A. H.; Franklin, S. R.; Carter, D. B.; Sethy, V. H.; Needham, L. M.; Jacobsen, E. J.; Von Voigtlander, P. F. Anxiolytic like effects of PNU-101017, a partial agonist at the benzodiazepine receptor. Psychopharmacology (Berl.) 1997, 131, 255-263.
19. A receptor subtypes: an in vivo approach to exploring the therapeutic and side effects of benzodiazepine-type drugs. CNS Spectr. 2005, 10, 40-48.
20. A modulators. CNS Spectr. 2005, 10, 21-27.
21. A receptor subtypes. Nature (London) 1999, 401, 796-800.
22. Collins, I.; Moyes, C.; Davey, W. B.; Rowley, M.; Bromidge, F. A.; Quirk, K.; Atack, J. R.; Mckernan, R. M.; Thompson, S. A.; Wafford, K.; Dawson, G. R.; Pike, A.; Sohal, B.; Tsou, N. N.; Ball, R. G.; Castro, J. L. 3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional selectivity for α2/α3-subtypes of human GABA(A) receptor-ion channels. J. Med. Chem. 2002, 45, 1887-1900.
23. Atack, J. R. Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Curr. Drug Targets: CNS Neurol. Disord. 2003, 2, 213-232.
24. A receptor. Bioorg. Med. Chem. Lett. 2004, 14, 3441-3444.
25. Carling, R. W.; Moore, K. W.; Street, L. J.; Wild, D.; Isted, C.; Leeson, P. D.; Thomas, S.; O'Connor, D.; Mckernan, R. M.; Quirk, K.; Cook, S. M.; Atack, J. R.; Wafford, K. A.; Thompson, S. A.; Dawson, G. R.; Ferris, P.; Castro, J. L. 3-phenyl-6-(2-pyridyl)-methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity γ-aminobutyric acid-A benzodiazepine receptor ligands with α2, α3, and α5-subtype binding selectivity over al. J. Med. Chem. 2004, 47, 1807-1822.
26. A a.2/3 receptor-ion channel ligands. Bioorg. Med. Chem. Lett. 2004, 14, 1679-1682.
27. Moulin, F.; Boosen, K.-J. Procedure for the synthesis of 1-substituted 4-aminopyrrolin-3-ones. DE 22 14 488, 1972.
28. Yokoyama, N.; Ritter, B.; Neubert, A. D. 2-Arylpyrazolo[4,3-c]-quinolin- 3-ones: novel agonist, partial agonist, and antagonist of benzodiazepines. J. Med. Chem. 1982, 25, 337-339.
29. Yuki, H.; Yamamoto, T.; Tohira, Y.; Aoki, B.; Kano, T. Studies on antiviral agents. II. Synthesis and biological activity of maleimide derivatives. Chem. Pharm. Bull. (Tokyo) 1967, 15, 1101-1106.
30. Augustin, M.; Köhler, M. Synthesis and spectra of substitution products of 2-chloro-maleinimides. J. Prakt. Chem. 1974, 316, 113-138.
31. Kano, S.; Yuasa, Y.; Shibuya, S.; Hibino, S. A new and facile synthesis of 5-arylpyrimidines and 4-arylpyrazoles. Heterocycles 1982, 19, 1079-1082.
32. Weber, G.; Hartung, J.; Beyer, L. Reactions of N-(morpholino- thiocarbonyl)-benzimidchloride with dinucleophiles. Z. Chem. 1986, 26, 70-71.
33. Nakamura, N.; Kishida, Y.; Ishida, N. Studies of acetylenic compounds. LVI. Syntheses of 4-isoxazolin-3-ones and 1-phenyl-3-hydroxypyrazoles. Chem. Pharm. Bull. 1971, 19, 1389-1394.
34. AH, A.; Saksena, R. K. Synthesis of some 1-substituted-4-phenyl-2-(3H)- imidazolethiones and their desulphurised products. J. Indian Chem. Soc. 1981, 58, 624-625.
35. 14 Can. J. Chem. 1956, 34, 530-540.
36. Barnish, I. T.; Fung, S. C.; Gibson, M. S.; Khan, S. R.; Pawalchak, G. A.; Tse, K. M. Benzohydrazides, benzothiohydrazides, and benzamidrazones as sources of 1,3,4(2H)-oxadiazolenones, 1,3,4(2H)-thiadiazolenones, and 1,2,4(5H)-triazolenones. J. Heterocycl. Chem. 1986, 23, 417-419.
37. File, S. E. What can be learned from the effects of benzodiazepines on exploratory behavior? Neurosci. Biobehav. Rev. 1985, 9, 45-54.
38. Löscher, W.; Potschka, H.; Rieck, S.; Tipold, A.; Rundfeldt, C. Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures. Epilepsia 2004, 45, 1228-1239.
39. Rostock, A.; Tober, C.; Dost, R.; Bartsch, R. AWD 131-138 is a potential novel anxiolytic without sedation and amnesia: A comparison with diazepam and buspirone. Naunyn-Schmiedeberg's Arch. Pharmacol. 1998, 358, P35.
40. Yasar, S.; Bergman, J.; Munzar, P.; Redhi, G.; Tober, C.; Knebel, N.; Zschiesche, M.; Paronis, C. Evaluation of the novel antiepileptic drug, AWD 131-138, for benzodiazepine-like discriminative stimulus and reinforcing effects in squirrel monkeys. Eur. J. Pharmacol. 2003, 465, 257-265.
41. A receptor. J. Pharmacol Exp. Ther. 2005, 314, 717-724.
42. A receptor through the benzodiazepine binding site. Neurosci. Lett. 1998, 245, 85-88.
43. A receptor subtype selectivity of the benzodiazepine receptor ligand ELB139. Abstract No. 678.2. Society for Neuroscience: Washington, DC, 2005.
44. Kochak, G. M.; Rakhit, A.; Hone, F.; Mahoney, C. J. Pharmacokinetic disposition of the novel atypical anxiolytic CGS 9896 in the cynomolgus monkey. Psychopharmacology (Berl.) 1988, 94, 332-335.
45. Lister, R. G.; Greenblatt, D. J.; File, S. E. A pharmacokinetic study of CGS-8216, a benzodiazepine receptor ligand, in the rat. Psychopharmacology (Berl.) 1984, 84, 420-422.
46. Zhang, W.; Koehler, K. F.; Zhang, P.; Cook, J. M. Development of a comprehensive pharmacophore model for the benzodiazepine receptor. Drug Des. Discov. 1995, 12, 193-248.
47. Diaz-Arauzo, H.; Koehler, K. F.; Hagen, T.; Cook, J. M. Synthetic and computer assisted analysis of the pharmacophore for agonists at benzodiazepine receptors. Life Sci. 1991, 49, 216.
48. Zhang, W.; Koehler, K. F.; Harris, B.; Skolnick, P.; Cook, J. M. Synthesis of benzo-fused benzodiazepines employed as probes of the agonist pharmacophore of benzodiazepine receptors. J. Med. Chem. 1994, 37, 745-757.
49. Martin, M. J.; Trudell, M. L.; Diaz-Arauzo, H.; Allen, M. S.; LaLoggia, A. J.; Deng, L.; Schultz, C. A.; Tan, Y. C.; Bi, Y.; Narayanan, K.; et al. Molecular yardsticks. Rigid probes to define the spatial dimensions of the benzodiazepine receptor binding site. J. Med. Chem. 1992, 35, 4105-4117.
50. Allen, M. S.; Skolnick, P.; Cook, J. M. Synthesis of novel 2-phenyl-2H-pyrazo1o[4,3-c]isoquinolin-3-ols: topological comparisons with analogues of 2-phenyl-2,5-dihydropyrazolo[4,3-c]quinolin-3(3H)-ones at benzodiazepine receptors. J. Med. Chem. 1992, 35, 368-374.
51. A receptors. J. Med. Chem. 1995, 38, 1679-1688.
52. Ananthan, S.; Clayton, S. D.; Ealick, S. E.; Wong, G.; Evoniuk, G. E.; Skolnick, P. Synthesis and structure-activity relationships of 3,5-disubstituted 4,5-dihydro-6H-imidazo[1,5-a][1,4]benzodiazepin-6-ones at diazepam-sensitive and diazepam-insensitive benzodiazepine receptors. J. Med. Chem. 1993, 36, 479-490.
53. Gu, Z. Q.; Wong, G.; Dominguez, C.; de Costa, B. R.; Rice, K. C.; Skolnick, P. Synthesis and evaluation of imidazo[1,5-a][1,4]-benzodiazepine esters with high affinities and selectivities at "diazepam- insensitive" benzodiazepine receptors. J. Med. Chem. 1993, 36, 1001-1006.
54. Wong, G.; Koehler, K. F.; Skolnick, P.; Gu, Z. Q.; Ananthan, S.; Schonholzer, P.; Hunkeler, W.; Zhang, W.; Cook, J. M. Synthetic and computer-assisted analysis of the structural requirements for selective, high-affinity ligand binding to diazepam-insensitive benzodiazepine receptors. J. Med. Chem. 1993, 36, 1820-1830.
55. Tebib, S.; Bourguignon, J. J.; Wermuth, C. G. The active analog approach applied to the pharmacophore identification of benzodiazepine receptor ligands. J. Comput.-Aided Mol. Des. 1987, 1, 153-170.
56. A/benzodiazepine receptor subtypes: binding affinities of substituted β-carbolines at recombinant α × β 2 subtypes and quantitative structure-activity relationship studies via a comparative molecular field analysis. Drug Des. Discov. 1999, 16. 55-76.
57. Harris, D. L.; DeLorey, T. M.; He, X.; Cook, J. M.; Loew, G. H. Determinants of recognition of ligands binding to benzodiazepine receptor/GABA(A) receptors initiating sedation. Eur. J. Pharmacol. 2000, 401, 271-287.
58. Huang, Q.; He, X.; Ma, C.; Liu, R.; Yu, S.; Dayer, C. A.; Wenger, G. R.; McKernan, R.; Cook, J. M. Pharmacophore/receptor models for GABA(A)/BzR subtypes (α1β3γ2, α5β3γ2, and α6β3γ2) via a comprehensive ligand-mapping approach. J. Med. Chem. 2000, 43, 71-95.
59. He, X.; Huang, Q.; Ma, C.; Yu, S.; McKernan, R.; Cook, J. M. Pharmacophore/receptor models for GABA(A)/BzR α2β3γ2, α3β3γ2 and α4β3γ2 recombinant subtypes. Included volume analysis and comparison to α1β3γ2, α5β3γ2, and α6β3γ2 subtypes. Drug Des. Discov. 2000, 17, 131-171.
60. Hansch, C.; Leo, A. Substituent constants for correlation analysis in chemistry and biology; Wiley: New York, 1979.
61. Goodford, P. J. GRID version 14. 1995. West Way House, Elms Parade, Oxford OX2 9LL, U.K., Molecular Discovery Ltd.
62. Harrison, P. W.; Barlin, G. B.; Davies, L. P.; Ireland, S. J.; Matyus, P.; Wong, M. G. Syntheses, pharmacological evaluation and molecular modelling of substituted 6-alkoxyimidazo[1,2-b]pyridazines as new ligands for the benzodiazepine receptor. Eur. J. Med. Chem. 1996, 31, 651-662.
63. Kahnberg, P.; Lager, E.; Rosenberg, C.; Schougaard, J.; Camet, L.; Sterner, P.; Ostergaard Nielsen, E.; Nielsen, M.; Liljefors, T. Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J. Med. Chem. 2002, 45, 4188-4201.
64. Yamagami, C.; Takao, N. Hydrophobicity parameters determined by reversal-phase liquid chromatography. V. Relationship between the capacity factor and the octanol-water partition coefficient for simple heteroaromatic compounds and their ester derivatives. Chem. Pharm. Bull. 1992, 40, 925-929.
65. Biltz, H.; Slotta, K. On the synthesis of hydantoines. J. Prakt. Chem. 1926, 113, 233-267.
66. Due, L.; McGarrity, J. F.; Meul, T.; Warm, A. Methyl (E)-4-Chloro-3- methoxy-2-butenoate: An extremely versatile four carbon building block. Synthesis 1992, 1992, 391-394.
67. Cheng, Y.-C.; Prusoff, W. H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 percent inhibition (150) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
68. Krall, R. L.; Penry, J. K.; White, B. G.; Kupferberg, H. J.; Swinyard, E. A. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia 1978, 19, 409-428.
69. Vogel, J. R.; Beer, B.; Clody, D. E. A simple reliable conflict procedure for testing anti-anxiety agents. Psychopharmacology (Berl.) 1971, 21, 1-7.
70. Litchfield, J. T.; Wilcoxon, F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 1949, 96, 99-113.
71. SYBYL version 6.5, 1998. 1699 S. Hanley Road, St. Louis, MO 63144-2913. USA, Tripos Inc.
72. TSAR version 3.1, 1997. The Medawar Centre, Oxford Science Park, Oxford OX4 4GA, UK, Oxford Molecular Group.
73. Gaillard, P.; Carrupt. P. A. CLIP, 1997. BEP-Dorigny, 1015 Lausanne, CH, University of Lausanne.